Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2018 Publisher: iNova Pharmaceuticals (New Zealand) Limited, c/- Simpson Grierson, 88 Shortland Street, Auckland 1141
ACUPAN is indicated for the relief of acute pain, including post-operative, dental, musculoskeletal and acute traumatic pain.
Dosage may range from 1 to 3 tablets three times daily depending on response. The recommended starting dosage is 2 tablets three times daily.
ACUPAN is not recommended for children under the age of 12 years.
Elderly patients may require reduced dosage due to slower metabolism. It is strongly recommended that the starting dose does not exceed one tablet three times daily as the elderly appear more susceptible to, in particular, the CNS side effects of nefopam. Some cases of hallucination and confusion have been reported in this age group.
Nefopam toxicity is manifested by neurological symptoms (coma, convulsions, hallucinations, agitation) and cardiovascular response (tachycardia with a hyperdynamic circulation).
Supportive treatment is suggested including forced emesis and diuresis. Oral administration of activated charcoal may help prevent absorption. Convulsions and hallucinations should be controlled (e.g. with diazepam IV or pr). Beta-adrenergic blockers may be of use in controlling the cardiovascular complications.
For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).
5 years.
Store below 25°C.
Blister foil packs of 90 tablets.
None.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
